Global career journey
The Novo Nordisk Graduate Programme is a 2-year journey that will take you through a minimum of three job rotations, with at least one based in our corporate headquarters in Denmark and another in one of our global affiliates.
During the programme you will gain a deep understanding of the company and our business, participate in global and national projects and build a strong international network of professional and dedicated colleagues.
After successfully completing the programme you will have the necessary professional and personal skills to embark on your global career with a permanent position at Novo Nordisk – perhaps as an executive assistant, internal consultant, specialist or international project manager.
Introduction: Learn about Novo Nordisk, our business segments, product portfolio, management framework and governance structure.
Training: Take part in intensive training for both professional and personal development.
Rotations: Complete a minimum of three job rotations, with at least one based in our corporate headquarters in Denmark and another in one of our global affiliates.
Mentoring: Get support from your programme manager who takes care of your overall development throughout your journey and a daily manager who is responsible for your development during each rotation.
Management exposure: Interact with international management throughout your rotations.
Networking: Gain knowledge and advice from professional and dedicated colleagues throughout the global organisation, including past graduates.
“I feel that the graduate programme is like a climbing wall. It will always be challenging, but it is up to you just how challenging you make it for yourself. You can choose how difficult the path is that you follow and therefore how big the personal reward is. I like this freedom and the trust that the company has in you to make your own personal choice.”
Maria Christiansen, former R&D Regulatory Affairs graduate
Novo Nordisk is the world leader in diabetes care, with 90 years of experience. In the biopharmaceuticals business sector, we have a leading position within the therapeutic areas of haemophilia management, growth hormone therapy and hormone replacement therapy.
With headquarters in Denmark, we employ more than 42,000 employees in 77 countries and market our products in 165 countries. We are an ambitious company and have experienced significant growth in recent years.
Novo Nordisk has been continuously ranked among the best companies to work for, both in Denmark and around the world. Our company culture, which has developed since the 1920s, is built on the work of past and present employees. The way we do things is called The Novo Nordisk Way.
Our values, business ethics and respect for society and the environment attract employees who are passionate about what they do and the difference they can make in the world.
This makes diabetes one of the leading causes of death across the globe. The disease currently affects 384 million people worldwide and this number is expected to grow to 592 million by 2035.
Millions of people all over the world rely on our products every day to ensure their health and well-being. We are committed to providing innovative treatments for people with diabetes. We invest in research to find better treatments and ultimately to find a cure for diabetes.
“I first really got to know about Novo Nordisk by attending a dinner at my university hosted by Novo Nordisk. I remember being impressed with the way employees spoke with such evident pride about what they did and who they worked for. Now, after completing the graduate programme, I can honestly say I have experienced the same sense of pride. We actually do live by our company vision and values. We do make a difference to society. And now I 'burn' to work for Novo Nordisk.”
Jimi Kehlet, former Finance graduate
We offer 16 different Graduate Programmes. Find your perfect match.
Diabetes is now a disease that affects more than 382 million people worldwide - according to the International Diabetes Federation (IDF). By 2030 the number is expected to grow to 592 million people. Join us and help to fight diabetes by offering high quality products.
Facts about diabetes
Operating profit after tax to net operating assets: 149%
Operating profit growth: 43%
Gross margin: 85%
Cash-to-earning (three-year average): 97%
Free cash flow: DKK 34.2 billion
*for further information take a look at Novo Nordisk's Annual Report